Publications

20Mo Time to Deterioration in Quality of Life in Patients (Pts) with Advanced Endometrial Cancer (Aec) Treated with Lenvatinib plus Pembrolizumab (L+P) or Treatment of Physician’s Choice (Tpc)

AuthID
P-00X-2PS

Author(s)

Lorusso, D

Colombo, N

Casado Herraez, A

Santin, A

Colomba, E

Miller, D

Fujiwara, K

Pignata, S

Baron-Hay, S

Ray-Coquard, I

Shapira-Frommer, R

Kim, Y

McCormack, M

Massaad, R

Martin Nguyen, A

Zhao, Q

McKenzie, J

Prabhu, V

Makker, V

Document Type

Article

Year published

2022

Published

in Annals of Oncology, ISSN: 0923-7534

Volume: 33, Pages: S391-S392

Indexing

Crossref^®1

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.annonc.2022.04.038

Source Identifiers

ISSN: 0923-7534

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

20Mo Time to Deterioration in Quality of Life in Patients (Pts) with Advanced Endometrial Cancer (Aec) Treated with Lenvatinib plus Pembrolizumab (L+P) or Treatment of Physician’s Choice (Tpc)

Useful Links

Get Help

Federated Authentication (Click on the image)

20Mo Time to Deterioration in Quality of Life in Patients (Pts) with Advanced Endometrial Cancer (Aec) Treated with Lenvatinib plus Pembrolizumab (L+P) or Treatment of Physician’s Choice (Tpc)

Useful Links

Get Help